BRPI0822061A2 - Moduladores do receptor canabinoide - Google Patents
Moduladores do receptor canabinoideInfo
- Publication number
- BRPI0822061A2 BRPI0822061A2 BRPI0822061-1A BRPI0822061A BRPI0822061A2 BR PI0822061 A2 BRPI0822061 A2 BR PI0822061A2 BR PI0822061 A BRPI0822061 A BR PI0822061A BR PI0822061 A2 BRPI0822061 A2 BR PI0822061A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor modulators
- cannabinoid receptor
- cannabinoid
- modulators
- receptor
- Prior art date
Links
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0724096A GB0724096D0 (en) | 2007-12-10 | 2007-12-10 | Cannabinoid receptor modulators |
| GB0813350A GB0813350D0 (en) | 2008-07-21 | 2008-07-21 | Cannabinoid receptor modulators |
| PCT/GB2008/004051 WO2009074782A1 (en) | 2007-12-10 | 2008-12-08 | Cannabinoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0822061A2 true BRPI0822061A2 (pt) | 2015-06-23 |
Family
ID=40344724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0822061-1A BRPI0822061A2 (pt) | 2007-12-10 | 2008-12-08 | Moduladores do receptor canabinoide |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8173680B2 (pt) |
| EP (1) | EP2231615A1 (pt) |
| JP (1) | JP2011506410A (pt) |
| KR (1) | KR20100091255A (pt) |
| CN (1) | CN101896465A (pt) |
| AU (1) | AU2008334489A1 (pt) |
| BR (1) | BRPI0822061A2 (pt) |
| CA (1) | CA2708706A1 (pt) |
| EA (1) | EA018900B1 (pt) |
| IL (1) | IL205980A0 (pt) |
| MX (1) | MX2010006109A (pt) |
| NZ (1) | NZ585704A (pt) |
| WO (1) | WO2009074782A1 (pt) |
| ZA (1) | ZA201004828B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI532725B (zh) * | 2010-01-26 | 2016-05-11 | 賽諾菲阿凡提斯公司 | 經氧取代之3-雜芳醯基胺基-丙酸衍生物及其作為藥物之用途 |
| KR101586714B1 (ko) * | 2011-09-30 | 2016-01-19 | 내셔날 헬스 리서치 인스티튜트 | 피라졸 화합물 |
| EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| CN104884057B (zh) | 2012-11-13 | 2019-08-20 | 美国政府(由卫生和人类服务部的部长所代表) | 大麻素受体介导的化合物 |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | 三唑酮化合物及其应用 |
| JP6762930B2 (ja) | 2014-05-09 | 2020-09-30 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用 |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| WO2023078333A1 (zh) * | 2021-11-03 | 2023-05-11 | 上海拓界生物医药科技有限公司 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
| JP2008517976A (ja) * | 2004-10-25 | 2008-05-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb1カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病1型、肥満及び関連症状の治療用の医薬組成物 |
| JP2008525404A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療剤 |
| EP1928859A1 (en) * | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazole derivates as cannabinoid receptor modulators |
| JP5069894B2 (ja) * | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
| WO2007106721A2 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| EP2029548A1 (en) * | 2006-05-31 | 2009-03-04 | Solvay Pharmaceuticals B.V. | Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists |
| GB0622569D0 (en) * | 2006-11-11 | 2006-12-20 | 7Tm Pharma As | Cannabinoid receptor modulators |
| CA2673177A1 (en) * | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Modulators of cb1 receptors |
-
2008
- 2008-12-08 EP EP08860004A patent/EP2231615A1/en not_active Withdrawn
- 2008-12-08 MX MX2010006109A patent/MX2010006109A/es not_active Application Discontinuation
- 2008-12-08 CN CN200880120649XA patent/CN101896465A/zh active Pending
- 2008-12-08 NZ NZ585704A patent/NZ585704A/xx not_active IP Right Cessation
- 2008-12-08 BR BRPI0822061-1A patent/BRPI0822061A2/pt not_active IP Right Cessation
- 2008-12-08 JP JP2010537504A patent/JP2011506410A/ja active Pending
- 2008-12-08 KR KR1020107015316A patent/KR20100091255A/ko not_active Withdrawn
- 2008-12-08 EA EA201000971A patent/EA018900B1/ru not_active IP Right Cessation
- 2008-12-08 US US12/745,708 patent/US8173680B2/en not_active Expired - Fee Related
- 2008-12-08 CA CA2708706A patent/CA2708706A1/en not_active Abandoned
- 2008-12-08 AU AU2008334489A patent/AU2008334489A1/en not_active Abandoned
- 2008-12-08 WO PCT/GB2008/004051 patent/WO2009074782A1/en not_active Ceased
-
2010
- 2010-05-26 IL IL205980A patent/IL205980A0/en unknown
- 2010-07-08 ZA ZA2010/04828A patent/ZA201004828B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011506410A (ja) | 2011-03-03 |
| EP2231615A1 (en) | 2010-09-29 |
| NZ585704A (en) | 2012-08-31 |
| MX2010006109A (es) | 2010-09-10 |
| WO2009074782A1 (en) | 2009-06-18 |
| US20100292273A1 (en) | 2010-11-18 |
| IL205980A0 (en) | 2010-11-30 |
| CA2708706A1 (en) | 2009-06-18 |
| US8173680B2 (en) | 2012-05-08 |
| ZA201004828B (en) | 2011-03-30 |
| CN101896465A (zh) | 2010-11-24 |
| AU2008334489A1 (en) | 2009-06-18 |
| KR20100091255A (ko) | 2010-08-18 |
| EA018900B1 (ru) | 2013-11-29 |
| EA201000971A1 (ru) | 2011-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012008159A2 (pt) | moduladores de receptor canabinoide | |
| ATE537157T1 (de) | Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren | |
| BRPI0813653A2 (pt) | Compostos de imidazotiazol moduladores de sirtuína | |
| BRPI0813651A2 (pt) | Compostos de tiazolopiridina moduladores de sirtuína | |
| DK2297100T3 (da) | Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer | |
| BRPI0923305A2 (pt) | moduladores de receptores toll-like | |
| DK2262808T3 (da) | Chemokinreceptormodulatorer | |
| DE602007006531D1 (de) | Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren | |
| BRPI0810815A2 (pt) | Dispositivo de fixação | |
| BRPI0822061A2 (pt) | Moduladores do receptor canabinoide | |
| BRPI0907844A2 (pt) | moduladores seletivos do receptor de andrógeno | |
| DE502007006120D1 (de) | Hochverfügbares Kommunikationssystem | |
| BRPI0813230A2 (pt) | Moduladores de calicreína 7 | |
| GB0701992D0 (en) | Grehlin Receptor Modulators | |
| DK2215803T3 (da) | Netværksadgang-autorisering | |
| BRPI0816154A2 (pt) | Moduladores canabinóides de 5-vinilfenil-1-fenil-pirazol substituídos | |
| EP2178371A4 (en) | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | |
| ATE475602T1 (de) | AUSGIEßER | |
| EP2227553A4 (en) | Lac expression system | |
| DK2147106T3 (da) | Expressionssystem | |
| GB0625196D0 (en) | Modulators of cannabinoid receptor | |
| IL200957A0 (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
| EP2187651A4 (en) | NETWORK SYSTEM | |
| BRPI0818773A2 (pt) | Moduladores de gama-secretase ligados a carbono | |
| ATE487723T1 (de) | Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |